about
Herpesvirus entry mediator ligand (HVEM-L), a novel ligand for HVEM/TR2, stimulates proliferation of T cells and inhibits HT29 cell growthStructures of human genes coding for cytokine LD78 and their expression4-1BB and Ox40 are members of a tumor necrosis factor (TNF)-nerve growth factor receptor subfamily that bind TNF receptor-associated factors and activate nuclear factor kappaBCytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptorCD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligandA new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosisNatural Killer Cell Immunomodulation: Targeting Activating, Inhibitory, and Co-stimulatory Receptor Signaling for Cancer ImmunotherapyCurrent status of immunotherapyThe Structure of the Trimer of Human 4-1BB Ligand Is Unique among Members of the Tumor Necrosis Factor SuperfamilyCD137 and CD137L signals are main drivers of type 1, cell-mediated immune responses4-1BB agonism: adding the accelerator to cancer immunotherapyNucleotide sequence of the third cytokine LD78 gene and mapping of all three LD78 gene loci to human chromosome 17Analysis of 4-1BBL and laminin binding to murine 4-1BB, a member of the tumor necrosis factor receptor superfamily, and comparison with human 4-1BBGalectin-9 controls the therapeutic activity of 4-1BB-targeting antibodiesCD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor.Anti-leukemia activity of MS-275 histone deacetylase inhibitor implicates 4-1BBL/4-1BB immunomodulatory functions.Activated T cells express a novel gene on chromosome 8 that is closely related to the murine ecotropic retroviral receptorCloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific.Therapeutic potential of anti-CD137 (4-1BB) monoclonal antibodies.Expression of 4-1BB and 4-1BBL in thymocytes during thymus regenerationA novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity.Rational combinations of immunotherapeutics that target discrete pathways.Signaling by tumor necrosis factor receptors: pathways, paradigms and targets for therapeutic modulation.Three agonist antibodies in combination with high-dose IL-2 eradicate orthotopic kidney cancer in mice.Role of 4-1BB receptor in the control played by CD8(+) T cells on IFN-gamma production by Mycobacterium tuberculosis antigen-specific CD4(+) T Cells4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapyBiphasic role of 4-1BB in the regulation of mouse cytomegalovirus-specific CD8(+) T cells4-1BB signaling breaks the tolerance of maternal CD8+ T cells that are reactive with alloantigens.Costimulation of mast cells by 4-1BB, a member of the tumor necrosis factor receptor superfamily, with the high-affinity IgE receptor.Exposure of a distinct PDCA-1+ (CD317) B cell population to agonistic anti-4-1BB (CD137) inhibits T and B cell responses both in vitro and in vivo.Bayesian approach to model CD137 signaling in human M. tuberculosis in vitro responses.Fas and its ligand in a general mechanism of T-cell-mediated cytotoxicityAgonist antibodies to TNFR molecules that costimulate T and NK cellsRole of 4-1BB:4-1BB ligand in cancer immunotherapy.Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities.Immune suppression or enhancement by CD137 T cell costimulation during acute viral infection is time dependent.Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD).Fas and tumor necrosis factor receptor-mediated cell death: similarities and distinctions.Expression of co-stimulator 4-1BB molecule in hepatocellular carcinoma and adjacent non-tumor liver tissue, and its possible role in tumor immunitySA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines
P2860
Q22003914-9D0DB7E6-60FE-45F4-8DA0-1706E3BB114DQ24300929-47E77675-9F20-419E-BBB9-385BE29CFA64Q24533857-2E7C7E96-BAED-46B8-8D5E-A403C5E526B3Q24597543-DEFAA778-CB3C-4502-B647-364998464745Q24647213-9B992A52-F283-4120-BF94-F125E28B5D8CQ24683805-D68F35FC-E873-40E7-908C-DA8F62293814Q26772347-27A5685D-3691-463E-ABE7-A876D13C1DF2Q26773314-0224AA9F-ECAC-4D89-B398-7ED40BB12D1CQ27658762-3F9B6B33-0AAF-4FD7-901A-B3ACB7FA37B6Q28072933-FEDE9DC9-A98D-431C-86F6-4369925715C5Q28079622-ABD94D02-DCB1-4076-9AF0-D404C58AA4E7Q28206246-AFAB3D41-27A5-4214-8C4B-BA108FC3FE2BQ28304298-DC915A59-0E79-49F0-BA2E-3DCF44E42CF0Q28656460-8EE169B5-C684-48B5-929C-74E9726289F6Q30573747-675295C9-A10E-4349-8B0B-353308503475Q30873726-CF41D8E7-C234-4272-BDF1-37971E96BB7FQ31057713-F5D436D2-ED56-408E-BD4D-30AF8E20467BQ33336314-8ABAF4CC-4399-4AA0-AB6E-FFE02758A41AQ33426409-4BA57B21-F110-46B4-B12D-9E389F77AC91Q33575781-2F7E5D2C-E551-42E0-B1A1-C572391D3C53Q33586493-24039304-E629-4DDC-9D4E-80193369D29CQ33606144-F4121F20-D1C8-4B04-B8BF-23008560BDBEQ33811753-0035863A-4547-4FB8-9684-0460659C1F1BQ33863928-AD337101-432B-4001-9ECF-DCC304175149Q33900380-BFAA8C30-41E3-41EE-8F93-36A04616BADCQ34180031-CB3EE6DF-40AD-4AEC-BEA7-CEA1745A953FQ34258584-84EB409E-139A-402E-B227-37683242991DQ34429170-81ECF4A0-DDAE-4BB7-BF4C-02BFB8C01331Q34485933-01E2A8DD-422A-4B01-84F3-4B4B16CA32B5Q34491239-4AA19F52-64AD-46E4-9191-1F1365086E7EQ34598341-19C2D41E-4BF9-4FC1-8A08-85BEF780D45FQ35326190-73625E45-CCCE-4F7B-8764-B84B5892541FQ35427446-57DD3F40-1A7D-4ADA-BE17-1BB0B440B081Q35606360-9432E9A2-72E9-4868-BBAF-11B838992DC7Q35850673-828D064C-4100-4C5A-AE47-DAA794877268Q35987596-9C22C868-8257-4B4D-AB87-2689F5F5DC2CQ36251308-E054BDA2-6EC5-4DD6-8D24-3B5AFBAB20BAQ36363545-4D1D3D71-092E-4348-AF3C-88222CFD459AQ36474377-F4694247-77A9-4965-B3E6-31DA86D8EC58Q36487245-38840CFA-5E6A-4E89-A371-1ACFCD5DEEB8
P2860
description
1989 nî lūn-bûn
@nan
1989 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի մարտին հրատարակված գիտական հոդված
@hy
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
name
cDNA sequences of two inducible T-cell genes
@ast
cDNA sequences of two inducible T-cell genes
@en
cDNA sequences of two inducible T-cell genes
@nl
type
label
cDNA sequences of two inducible T-cell genes
@ast
cDNA sequences of two inducible T-cell genes
@en
cDNA sequences of two inducible T-cell genes
@nl
prefLabel
cDNA sequences of two inducible T-cell genes
@ast
cDNA sequences of two inducible T-cell genes
@en
cDNA sequences of two inducible T-cell genes
@nl
P2860
P3181
P356
P1476
cDNA sequences of two inducible T-cell genes
@en
P2093
S M Weissman
P2860
P304
P3181
P356
10.1073/PNAS.86.6.1963
P407
P577
1989-03-01T00:00:00Z